Therapy Detail

Therapy Name Tinostamustine
Synonym
Therapy Description

Tinostamustine (EDO-S101) comprises the structure of the DNA alkylating drug bendumustine combined with the pan-HDAC inhibitor vorinostat, which may both induce DNA damage and inhibit DNA repair resulting in increased tumor cell death (PMID: 28753594).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Tinostamustine EDO-S101 Chemotherapy - Alkylating 14 HDAC Inhibitor 35 Tinostamustine (EDO-S101) comprises the structure of the DNA alkylating drug bendumustine combined with the pan-HDAC inhibitor vorinostat, which may both induce DNA damage and inhibit DNA repair resulting in increased tumor cell death (PMID: 28753594).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown multiple myeloma not applicable Tinostamustine Preclinical - Cell culture Actionable In a preclinical study, treatment with EDO-S101 induced apoptosis and decreased viability of a multiple myeloma cell line in culture (PMID: 28753594). 28753594
Clinical Trial Phase Therapies Title Recruitment Status
NCT03345485 Phase Ib/II Tinostamustine Study of the Safety, Pharmacokinetics and Efficacy of EDO-S101, in Patients With Advanced Solid Tumors Recruiting
NCT03452930 Phase I Tinostamustine EDO-S101 for MGMT Unmethylated Glioblastoma (nGBM) Recruiting
NCT02576496 Phase I Tinostamustine Study of EDO-S101, A First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies Recruiting
NCT03687125 Phase Ib/II Tinostamustine Tinostamustine Conditioning and Autologous Stem Cell (TITANIUM1) Active, not recruiting